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Abstract 14	
 15	
In the human kidney, the repair ability is limited and, after repeated injury, a maladaptive 16	
response may be triggered, characterized by fibrosis and loss of function. In particular, the 17	
transcription patterns that characterize nephrogenesis of foetal renal progenitors are only 18	
partially activated during adult repair. Data from the literature support the role of segment 19	
restricted progenitor resident cells supporting renal healing of adult kidneys. In this review, we 20	
will discuss the evidence for the localization and involvement of functional human renal 21	
progenitor cells in renal repair, and discuss the controversial issue of a fixed or plastic 22	
population induced by the microenvironment. We will also discuss the strategies supporting the 23	
generation of renal progenitor cells from pluripotent stem cells or directly from differentiated 24	
cells. Finally, pre-clinical data on the potential therapeutic use of human foetal cells, adult 25	
progenitors or adult renal cells will be addressed. 26	
 27	
 28	
 29	
 30	
Introduction 31	
2		
 1	
 2	
Nowadays, kidney diseases are considered a research and public health priority, as their 3	
incidence is increasing worldwide with augmented morbidity and mortality1. Acute kidney injury 4	
(AKI) is characterized by an acute loss of kidney cells and functions, resulting from ischemic, 5	
toxic or inflammatory insults, and associates with in-hospital morbidity and mortality, despite 6	
the supportive therapies. In addition, acute insults or chronic injury may lead to the progressive 7	
loss of nephrons and renal functions, requiring renal replacement therapy by dialysis or 8	
transplantation. 9	
 The development of acute and chronic renal disease is strictly correlated with an 10	
impaired ability of renal repair to regain function after injury. Neo-nephrogenesis does not occur 11	
in the adult human kidney. However, the kidney retains some regenerative potential. Several 12	
studies have provided evidence to suggest that repair activities in adult kidneys are supported 13	
by resident nephron cells surviving injury, with a dedifferentiated phenotype and a clonal 14	
proliferative potential2, 3. However, the transcription patterns that characterize nephron 15	
generation, known to be present in foetal renal progenitors, are only partially activated during 16	
adult kidney repair, indicating differences and weaknesses of the repair process4. 17	
Consequently, the repair ability in adult tissue is limited and, after repeated injury, results in a 18	
maladaptive response, ensuing in fibrosis and loss of function. In fact, it is well established that 19	
patients with AKI or subclinical rejections may develop chronic kidney disease (CKD) 5. Finally, 20	
chronic renal failure is characterized by a loss of regenerative processes.  21	
In the present review, we will examine the data relative to the presence, the isolation and the in 22	
vitro generation of renal progenitor-like cells (RPCs), focusing on results obtained in humans, 23	
and discuss their potential therapeutic applications.  24	
 25	
A. Presence of progenitors or progenitor-like cells (RPCs) in the renal tissue 26	
 27	
RPCs in the foetal kidney 28	
 In all mammals, the development of mature nephrons involves the differentiation and 29	
organization of RPCs of mesenchymal origin. From the embryonic metanephros, reciprocal 30	
inductive interactions between the metanephric mesenchyme and the ureteric bud are required 31	
for kidney formation6. The cap mesenchyme represents the niche where renal progenitors 32	
3		
undergo mesenchymal-to-epithelial transition7, 8. These committed progenitors sequentially 1	
form pre-tubular aggregates, renal vesicles and C- and S-shaped bodies, leading to the 2	
glomerular and renal tubule compartment6. 3	
 Embryonic progenitors represent the prototypes of the renal cell population that are able 4	
to proliferate and differentiate towards different types of nephron epithelia. Therefore, defining 5	
the cell programs involved in renal progenitor function may provide important knowledge for the 6	
mechanisms of renal regeneration in the adult kidney. Several transcription factors and 7	
markers have been identified to characterize RPCs in the developing kidney, and most of our 8	
knowledge derives from mouse studies. In particular, RPCs in the mouse embryo were first 9	
characterized as a multipotent population expressing Six2 with self-renewing capability8. In 10	
addition, fate mapping in the mouse embryo led to the identification of several genes marking 11	
progenitors and involved in their maintenance and differentiation9, including the Sall110, 12	
EYA111, OSR112, CITED17 genes and the transcriptional factors PAX213 and WT114. Other 13	
markers were reported as being involved in segment specification, such as the Wnt target gene 14	
Lgr5 responsible for generating the thick ascending limb of Henle’s loop and the distal 15	
convoluted tubule15, or Notch2, which appears to regulate the shift from self-renewal to 16	
differentiation, specifying proximal tubules16. 17	
 In humans, foetal RPCs have been characterized to a lesser extent. Many results were 18	
obtained from an extensive gene-expression profile analysis in Wilm’s tumour, as this 19	
paediatric tumour is characterized by loss of terminal progenitor differentiation17. The 20	
population expressing foetal renal progenitor markers Six2, Wt1, Cited1, and Sall1 was shown 21	
to co-express NCAM and FZD718. By contrast, the CD133 marker appeared to be expressed 22	
by Epcam+ cells with a more differentiated phenotype18. Indeed, these two surface markers, 23	
NCAM and CD133, were successfully exploited for the isolation of RPCs from the foetal renal 24	
kidney. NCAM1 has been reported to facilitate selection for a nephron lineage that includes 25	
SIX2-positive cap mesenchyme cells with in vitro clonogenic and stem/progenitor properties19. 26	
While NCAM1 is absent in the normal adult human kidney, CD133 is expressed from the 27	
vesicle state onwards20,21, and is maintained in scattered cells in the adult renal tissue22. 28	
 In the adult kidney, the nephrogenic mesenchymal progenitor population disappears, 29	
maybe due to the loss of its niche23. RPCs are only induced in the nephrogenic pathway until 30	
the 34th week of gestation19, and no equivalent cell types can be identified in the adult kidney. 31	
4		
Even during repair, only a partial reactivation of certain foetal transcriptional programs occurs, 1	
such as induction of Pax2, BMI-1 and Six2 4, 24. 2	
 3	
RPCs in the adult kidney  4	
 Even though the ability of whole nephron regeneration is lost in the human adult kidney, 5	
organ homeostasis and the repair process require cells with progenitor-like characteristics. This 6	
population is required for the continuous replacement of cells lost during physiological 7	
processes. In fact, it is estimated that about 6000 cells, which derive from different nephron 8	
segments, are lost every hour in the urine (Prescott). In addition, repair after acute injury 9	
requires repopulation of tubular compartments. Initial investigations in the stem cell field 10	
supported the search for residual stem cells involved in these processes, whereas subsequent 11	
studies failed to identify cells with multipotent nephron-generating ability.  12	
 13	
  Murine studies 14	
   15	
The presence of RPCs and their possible role in renal regeneration has been investigated 16	
thanks to lineage tracing and fate-mapping techniques. The involvement of nephron resident 17	
cells in tubule regeneration was first demonstrated by Humprehy and colleagues25. Using 18	
genetic label of mesenchyme-derived renal epithelial cells, they could exclude the role of 19	
interstitial or bone marrow derived stem cells in repair after acute injury25. In a subsequent 20	
study, double tracking of tubular cells following acute ischaemic damage showed a random 21	
proliferation of tubular epithelial cells. These results have been attributed to a proliferation of all 22	
cells within a specific tubular segment. However, they do not exclude the possibility that a 23	
subpopulation of cells with progenitor properties may proliferate and repair the tubular 24	
segments, as suggested by other reports2.  25	
Using rainbow mice, the group of Dekel clearly identified that cells with segment-specific clonal 26	
and extensive proliferation ability can support kidney epithelia self-renewal throughout an entire 27	
lifetime2. Indeed, single colour-expressing cell colonies were detectable along kidney segments 28	
at 6 months after cell tagging, thus indicating the presence of clone-forming cells2. In addition, 29	
segment-specific cells with clonogenic ability also contributed to the repair of specific nephron 30	
segments, suggesting that nephron regeneration is granted by segment-committed clonogenic 31	
RPCs.  32	
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From all these observations, it can be inferred that the process of regeneration occurring in 1	
renal tubules relies on resident intratubular cells with a limited segment specific regenerative 2	
potential and with clonogenic and proliferative ability, thus representing a “functional” 3	
population of renal progenitor cells. However, the identity of these cells remains elusive, as 4	
they may possibly derive either by a pre-determined population of RPCs, or by a plastic 5	
phenomenon in which cells transiently acquire a RPC phenotype. 6	
Recently, a subpopulation of proximal tubular cells (“scattered tubular cells”, STC) was 7	
identified and genetically labelled. STCs appeared as an injury-inducible population, as their 8	
number did increase when labelled during ischaemic injury27. Although these data do not 9	
exclude a concomitant activation of renal progenitors in the regenerative process, they 10	
underline the capability of tubular differentiated cells to acquire a progenitor-like function and 11	
suggest that the plasticity of the tubular phenotype might be involved in this process (review 12	
Berger).  13	
In contrast to the tubules, the glomerular regenerative potential is quite limited. RPCs identified 14	
in Bowman's capsule appeared to contribute to podocyte regeneration, migrating onto the 15	
glomerular tuft, only during infancy to adolescence, whereas this process was not observed in 16	
adult life28. In addition, using label retention, intratubular slow cycling populations have been 17	
confirmed in proximal and distal tubules and in the thick ascending limb of the Henle’s loop29 18	
as well as in the papilla30. Furthermore, by expression of stem-cell markers, specific 19	
populations of progenitors have been detected as nFatC1+ cells in proximal tubules31 and as 20	
Lgr5 or c-kit expressing cells in the thick ascending limb of Henle's loop and distal convoluted 21	
tubules15,32. It is possible that distinct populations of segment progenitors might be 22	
characterized by different marker expression (Table I). 23	
 24	
 Human studies 25	
 In human tissue, using the AC133 antibody, which recognizes a glycosylation-26	
dependent epitope of prominin (CD133), expressed by haemopoietic stem cells33,34, a discrete 27	
population of CD133+ cells was detected in different segments of the nephron, namely the 28	
Bowman’s capsule, proximal and distal tubules, as well as in the inner medullary papilla region, 29	
including Henle’s loop and the S3 limb segment35-42 (Table I). CD133+ cells co-expressed the 30	
mesenchymal marker vimentin and cytokeratins 7 and 19, not expressed by the bulk of tubular 31	
epithelial cells37,39 (Table II). In the Bowman’s capsule, CD133+CD24+ cells localized at the 32	
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urinary pole, whereas cells expressing differentiation markers of podocytes increased toward 1	
the vascular pole40. In proximal tubules, CD133+ cells were mainly located in the tubular plicae 2	
where proximal convoluted tubules make hairpin turns3, and co-expressed megalin and 3	
aquaporin-136,41. In the distal nephron, small clusters of CD133+CD24+ cells were detected in 4	
the portion of the distal convoluted tubule that makes contact with the vascular pole of the 5	
glomerulus, and these cells also co-stained for the thiazide-sensitive Na/Cl cotransporter41. At 6	
variance, CD133+ cells in the medulla lacked expression of differentiation markers36. 7	
Moreover, the CD24+, CD133+, or vimentin-expressing scattered cells observed within the 8	
proximal tubules were shown to co-express known markers of scattered cells, such as annexin 9	
2, claudin-3 and 7, S100A6, and CXCR437, as well as collagen 7A1 and the tight junction 10	
protein claudin-13 (Table II). As most experiments have been performed on normal portions of 11	
kidneys derived from tumour-bearing patients, it has been suggested that CD133 expression 12	
can be induced. Recently, CD133-expressing cells (from 3 to 12%) have also been shown to 13	
be present in normal renal tissue of pre-transplant biopsies from native donors of all ages, 14	
indicating their presence at a physiological level3. However, this result conflicts with the 15	
observation that scattered tubular cells are absent in normal juvenile tissue in rodents37. 16	
 A detailed analysis of scattered intratubular cell morphology, by electron microscopy, 17	
indicated a striking difference with respect to adjacent 'normal' proximal tubular cells, as they 18	
appeared smaller, lacked brush border microvilli and showed fewer mitochondria37. The lack of 19	
mitochondria in scattered cells has been further confirmed by electron microscopy using gold-20	
conjugated vimentin antibodies, as well as by double staining of renal tissue with CD133 and 21	
mitochondrial markers3. In the light of the role of CD133 in glucose uptake42,43, the CD133-22	
expressing population may possess a particular anaerobic metabolism, which could explain 23	
their ability to survive following injury3. Indeed, Bourseau- Guilmain et al.42 showed that CD133 24	
inhibits endocytosis of the transferring receptor, thus resulting in inhibition of iron uptake and 25	
consequently of mitochondrial activity. In turn, CD133 expression has been related to glucose 26	
uptake in glioma cells43. Taken together, these data lead to the proposal that CD133 might be 27	
involved in the regulation of glycolytic metabolism. Indeed, in an explant model in which human 28	
renal tissue was subjected to ischaemia reperfusion damage, the CD133+ scattered cells did 29	
not undergo necrosis and remained anchored to the basal membranes, whereas the detached 30	
cells were negative for these markers3. This observation supports the notion of a 31	
physiologically distinct population with high resistance to damage, rather than an injury-induced 32	
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population. It does not address, however, whether the CD133+ cells are a fixed population or a 1	
transient functional state modulated by microenvironmental stimuli.  2	
  3	
RPCs in renal pathology 4	
 Whatever their origin, the CD133 population appears to play a role in acute tissue repair 5	
of the tubular compartment. Conversely, their activation in glomeruli appears to be related to 6	
glomerular diseases20. Loverre et al. first reported that CD133+ cells were significantly 7	
increased in patients with delayed graft function resulting from an acute injury, compared to the 8	
pre-transplant biopsy or to patients with early graft function44. Three other studies reported an 9	
increase of tubular CD133+ cells with respect to normal tissue, after acute tubular necrosis in 10	
transplanted patients or in proteinuric glomerular diseases3,37,41. The involvement of these cells 11	
in renal repair is strongly supported by the evidence that almost all proliferating cells in acute 12	
tubular injury biopsies were CD133/CD24 positive. In addition, these cells co-expressed the 13	
KIM injury marker37. Interestingly, the number of CD133+ cells in patients with acute tubular 14	
necrosis appeared to be a predictive marker of tissue recovery45. 15	
 The presence of cells expressing progenitor markers was also reported in chronic tissue 16	
injury.  Stripes and clusters of proliferating tubular CD133+ cells were detected in biopsies of 17	
patients with chronic tubule-interstitial damage due to urinary obstruction or focal segmental 18	
glomerulosclerosis (FSGS), suggesting the activation of mechanisms for tissue repair3,41. It 19	
would be interesting to understand whether the loss of the regenerative ability in chronically 20	
damaged human tissue could possibly be ascribed to cell exhaustion, or to mechanisms of cell 21	
senescence. Interesting, blocking the G2/M phase of the cycle was related to a senescent 22	
secretory phenotype occurring in tubular cells after repeated injury46. 23	
The involvement of progenitor-like cells with enhanced proliferative ability also occurs when 24	
abnormal proliferation underlines pathological settings, such as in the glomerular tuft during 25	
acute glomerulonephritides and in cells forming cysts in polycystic kidney disease. Indeed, 26	
proliferation of CD133+ cells was reported in glomerular hypercellular lesions, and 27	
(pseudo)crescents leading to Bowman's space obliteration occurring in collapsing 28	
glomerulopathy and crescentic glomerulonephritis, and within glomerular tip lesions at the 29	
urinary pole of the Bowman's capsule20,47. Similarly, in polycystic kidney disease, all cyst-lining 30	
cells strongly expressed CD13348.  31	
 32	
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 The results of the above-mentioned studies in human renal tissue clearly indicated the 1	
existence, in different nephron segments, of cells that can be defined as adult RPCs by a 2	
functional definition of progenitor cells, as they are able to proliferate, participate in tissue 3	
homeostasis and repair, and survive to injury. In addition, from a phenotypic point of view, they 4	
lack a differentiated phenotype and express stem-related markers. It seems plausible that adult 5	
human CD133+ RPCs represent the same population described as segment-restricted 6	
progenitors in mice. The debate on the fixed nature of renal progenitors or on the induction of 7	
their phenotype is of difficult answer, as no lineage tracing can be applied to human studies.  8	
However, cellular plasticity is the most likely explanation. This has been suggested for organs 9	
other than kidney, such as the lung, bone marrow and pancreas. Indeed, increasing body of 10	
evidence supports the argument that the stem/progenitor-related phenotype is not static but 11	
rather a dynamic process characterized by continuous cycle and regulated by microvesicle-12	
related microenvironmental stimuli (Quesemberry Leukemia. 2014 Apr;28(4):813-22.).  13	
 14	
 15	
B. RPC cultures  16	
 Most of the data supporting the phenotypic and functional characteristics of RPCs have 17	
derived from the analysis of their behaviour and phenotype once cultured and isolated. Many 18	
different RPCs with repair ability have been isolated from adult mouse tissue using stem-19	
related characteristics such as marker expression, BrdU label retention, side population 20	
labelling or clonogenicity49-53. These cell lines showed variability in marker expression, origin, 21	
potency and differentiation ability. More homogeneous and unifying results were obtained in 22	
humans, using the strategies depicted in the following paragraphs. 23	
 24	
Isolation and characterization of RPCs from human renal tissue  25	
 We first isolated and characterized cells expressing the AC133-detected CD133 stem 26	
cell marker from the human renal cortex54. CD133+ cells were subsequently isolated from the 27	
Bowman’s capsule of human glomeruli35, as well as from the inner medulla36,38. These CD133+ 28	
populations, isolated from different nephron segments, shared similar phenotypic properties, as 29	
they all expressed foetal renal markers, such as Pax-2, Wt-1, and CD24, along with several 30	
mesenchymal stem cell markers, such as CD29, CD73 and CD90, with minor variations in 31	
expression levels, possibly related to cell culture conditions. This was further confirmed by 32	
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analysis of a gene expression profile, which clustered CD133+ cells from glomeruli and tubules 1	
against epithelial differentiated cells55. However, some genes were differentially expressed, 2	
including VCAM- 1, also known as CD106, which was expressed approximately 300-fold more 3	
in CD133+CD24+ cells obtained from glomerular outgrowths than from tubules41. Functionally, 4	
CD133+ RPCs were clonogenic, and, most importantly, differentiated into tubular cells of 5	
different nephron segments and glomerular podocytes after appropriate stimulation35,54. When 6	
injected within Matrigel in vivo in immunodeficient mice, RPCs also generated tubular 7	
structures expressing nephron segment markers36,54. In addition, CD73+/CD133+ RPCs 8	
isolated from the inner medulla were shown to synthesize and release erythropoietin under 9	
hypoxia56. 10	
 As CD133 cultures were generated by cell sorting, they should represent the CD133 11	
expressing cells in the renal tissue. However, it has been noticed that total cell cultures of 12	
kidney cells may express CD133 at fairly high levels57. A possible explanation is the selective 13	
ability of CD133+ RPCs to survive in culture. Another possibility is that CD133 could also be 14	
acquired by tubular cells due to culture-induced dedifferentiation. This has been recently 15	
excluded for podocytes that did not participate in the generation of CD133+ cells cultured from 16	
urine58 but it could be a possible mechanism in tubular-derived CD133+ cell culture. In any 17	
case, plasticity of cultured CD133+ RPCs may provide insights in the mechanisms of kidney 18	
repair and could be exploited for renal regeneration.  19	
 Other selection strategies based on functional assays were utilized to identify and select 20	
RPCs from human renal tissue. For example, cells were sorted based by means of a functional 21	
assay that which evaluates the stem-related activity of ALDH39. ALDHhigh cells expressed 22	
CD133 and vimentin appeared were similar in appearance to CD133- sorted cells39. Another 23	
functional assay commonly used for stem cell isolation is the ability to growth as spheres.  The 24	
so-called nephrospheres contained cells at different levels of maturation59. Selection of the 25	
quiescent cells within the nephrospheres using retention of the PKH26   dye identified a self-26	
renewing population capable of multiple differentiations into cells with epithelial, endothelial 27	
and podocytic characteristics. Interestingly, these cells also expressed a CD133+/CD24− 28	
phenotype59. 29	
 A different approach was proposed by the group of Dekel, who exploited the neo-30	
expression of the foetal marker NCAM, by a fraction of human renal cells in culture57. Indeed, 31	
this marker is absent in normal adult renal tissue, but it can be reactivated after ischaemia-32	
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reperfusion injury60. NCAM+ RPCs were shown to be enriched in renal progenitor/stem 1	
transcriptional factors (SIX2, SALL1, PAX2, and WT1 and Oct4) and to present a 2	
mesenchymal phenotype. In addition, NCAM positive cells showed enhanced functional 3	
properties related to stemness (clonogenicity, sphere-forming ability and tubulogenic 4	
differentiation on single-cell grafting in chick chorioallantoic membranes and mice) 57.  5	
All the described cell lines of human RPCs possess a limited life span and undergo 6	
senescence over time. It is reasonable to suggest that no robust, long-term culture system 7	
currently exists that is capable of maintaining potent, clonal expansion of adult progenitors over 8	
long periods of time under defined conditions. 9	
 10	
Isolation of RPCs from urine 11	
 It has been shown that freshly voided urine66 and urine from the upper urinary tract67 12	
contain multipotent stem cells. In addition, CD133/CD24 RPCs have been isolated and cultured 13	
from the urine of normal subjects as well as from patients with kidney disorders58. Urine-14	
derived RPCs were similar to tissue-derived RPCs at a phenotypic and functional level, and 15	
differentiated into both tubular cells and podocytes. In addition, urine-derived CD133/CD24 16	
RPCs were used for the diagnosis of glomerular genetic disorders58. 17	
The release of foetal urine into the amniotic fluid represented the rationale in the search for 18	
RPCs in the amniotic fluid. Da Sacco et al.68 have successfully isolated, from the amniotic fluid, 19	
a sub-population of metanephric mesenchyme-like cells committed to nephron lineages, and 20	
capable of differentiating into podocytes.  21	
Urine-derived cells may represent an attractive source of autologous cells for cell therapy. In 22	
addition, they could be exploited as diagnostic tool for genetic glomerular disorders. 23	
 24	
Isolation of renal mesenchymal stromal cells from renal tissue 25	
 Cells with a mesenchymal origin and multipotent properties are known to be present in a 26	
population adjacent to endothelial cells of the microvasculature, on the basis of marker 27	
expression (CD146+ NG2+ CD140b+), and may possibly contribute to tissue support61. Renal 28	
mesenchymal stromal cells (MSCs) isolated from the mouse kidney, differentiated in vivo into 29	
renin-producing cells62, indicating a commitment towards renal cell types. Interestingly, a 30	
recent paper from Little’s group showed that MSC-like cells from mouse collecting ducts can be 31	
isolated from adult murine kidneys due to a phenomenon of epithelial-mesenchymal transition 32	
11		
after long-term culture in vitro63. The obtained cells give rise to a long-term self-renewing MSC 1	
population, which shows the characteristic pan-mesodermal differentiation. In addition, renal 2	
MSCs possess the ability to integrate into aquaporin 2–positive medullary collecting ducts 3	
when injected into the kidneys of neonatal mice, unlike bone marrow-derived MSCs64. The 4	
differentiation of renal MSCs into renal tissue is supported by data showing the expression of a 5	
selected pattern of genes in renal MSCs, compared with MSCs of marrow origin, possibly 6	
related to a memory of tissue origin64. This suggests that renal MSCs may display organ-7	
specific regenerative capacities that are highly superior to those of MSCs from unrelated 8	
organs, which could thus be exploited for therapeutic applications64.  9	
In human kidneys, resident MSCs were investigated in glomeruli, based on their vascular 10	
nature, and characterized as CD133-/CD146+ cells65. Glomeruli-derived MSCs displayed self-11	
renewal capability, clonogenicity, and the ability to differentiate into the different glomerular cell 12	
types (endothelial, mesangial and epithelial cells). Evidence that glomerular MSCs do not 13	
derive from the bone marrow has been provided by detection of MSCs derived from donors in a 14	
sex-unmatched transplant65. 15	
 16	
 17	
C. Modulation or induction of an RPC phenotype 18	
Micro-environmental stimuli for RPC modulation  19	
 As described above, the nature of the cells involved in kidney homeostasis/regeneration 20	
is unclear, and further studies are required to define the mechanisms involved in their possible 21	
activation69. According to the idea of a plastic phenotype of RPCs, it can be speculated that the 22	
progenitor phenotype could be a consequence of a cell cycle state, or rather it may result from 23	
the modulation of growth and differentiation of resident cells by external stimuli. Interestingly, 24	
soluble signals released by a diseased kidney were shown to induce the generation of 25	
scattered tubular cells in the contralateral kidney in mice, supporting the hypothesis of cell 26	
reprogramming by the microenvironment 27,70. Knowledge of the activating mechanisms 27	
involved in the modulation of the RPC phenotype could be relevant, both in terms of a 28	
pharmacological approach for local cell modulation, and in terms of possible ex vivo treatment 29	
of cells before their in vivo injection. 30	
12		
 A hypoxic environment appears to activate RPC properties. Hypoxia was reported to 1	
increase proliferation, clonogenicity and CD133 expression in RPCs isolated from the inner 2	
medulla36. Indeed, consistent HIF-1 activation was shown in these RPCs, possibly related to 3	
the hypoxic condition of the tissue of origin. The mechanism of hypoxia-related acquisition of 4	
progenitor properties may rely on the hypoxia-induced expression of the stem cell transcription 5	
factor OCT4A and its regulation by micro-RNA 14536. In addition, in cortical RPCs, a 6	
comparative analysis between RPCs and differentiated tubular cells identified two microRNAs 7	
involved in the regulation of stemness and differentiation of RPCs. In particular, miR-1915 8	
targeted the progenitor factors CD133 and PAX2, and miR-1225-5p targeted toll-like receptor 2 9	
(TLR2) expression, which is a key gene of damage signalling, which is up-regulated in RPCs71. 10	
In addition, Wnt signalling has been linked to RPC maintenance in the mouse, as renal cells 11	
with cloning ability showed increased activation of this pathway2. 12	
RPC generation from iPS or direct generation of inducible-RPC 13	
 Recent advances in the stem cell field could facilitate the generation of RPCs with 14	
nephrogenic potential (metanephric mesenchyme-like progenitors) from somatic cells, through 15	
the generation of inducible pluripotent stem cells (iPS) or directly from embryonic stem cells. 16	
The obvious advantage in the use of iPS is the possible generation of autologous cells and the 17	
lack of ethical issues. IPS were successfully shown to generate entire renal structures as well 18	
as renal organoids (ref). Moreover, two recent investigations refined the methods for human 19	
intermediate mesoderm progenitor generation from iPS using small chemical inhibitors, 20	
obtaining high efficiency and rapidity73,74. Araoka et al 73 successfully generated human 21	
intermediate mesenchymal progenitors (80% efficiency in 5 days) from iPS using retinoids and 22	
an activator of the Wnt pathway. The resulting cells showed the ability to differentiate into 23	
multiple cell types, and to form renal tubule-like structures. Similarly, Lam et al.74, by using 24	
retinoic acid and Wnt activator plus FGF2, produced intermediate mesenchymal cells within 3 25	
days. In addition, intermediate progenitors, if treated with FGF9 and activin, further 26	
differentiated into Six2+ metanephric mesenchyme progenitors. The generation of autologous 27	
cells with nephrogenic potential is highly promising in regenerative medicine of the kidney. 28	
However, tumorigenic potential of these cells and the scarce proliferation of iPS-differentiated 29	
cells still represent a significant limitation for their application.  30	
13		
 An alternative approach for RPC generation is the direct reprogramming of renal cells 1	
into progenitors. The group of Little successfully identified, by means of sequential screening, a 2	
cocktail of six genes (SIX1, SIX2, OSR1, EYA1, HOXA11, and SNAI2) able to reprogram 3	
human tubular cells into metanephric mesenchymal progenitors75. These progenitors showed 4	
the capacity to contribute to the nephrogenic compartment of a developing embryonic kidney 5	
ex vivo. Although this study represents a huge step towards the generation of progenitors for in 6	
vivo use, improved optimization of transfection, including the use of non-integrating or inducible 7	
vectors, as well as establishing ideal growth conditions is still required for therapeutic 8	
applications.  9	
D. Therapeutic use of RPCs in experimental models of kidney injury 10	
Cell therapy is clearly the most promising tool to provide regenerating cells/stimuli to the renal 11	
tissue (Table III, IV and Figure 1). In zebrafish, Diep and colleagues76 clearly showed that 12	
transplanting RPCs with nephrogenic potential generated multiple nephrons. In the fish the 13	
mesenchymal nephron progenitor population persists supporting de novo nephrogenesis. 14	
In human, this potential is not present in the adult and therefore RPCs do not generate new 15	
nephrons, but rather may support the process of nephron repair. However, a mesenchymal 16	
nephron progenitor population could facilitate the creation and integration of new 17	
nephrons. 18	
Cell therapy with embryonic/ foetal RPCs 19	
 Human RPCs isolated from foetal kidneys were shown to exert a therapeutic effect in 20	
acute and chronic renal injury. CD24+/CD133+ RPCs isolated from human foetal tissue 21	
ameliorated renal function after glycerol-induced AKI21. Using this model, the effects were 22	
comparable to those of adult RPCs. Human foetal nephron progenitor NCAM+ cells were 23	
tested in the 5/6-nephrectomy kidney injury model characterized by loss of renal mass and 24	
progression. In this model, cells were administered directly into the renal parenchyma in three 25	
consecutive injections, and were shown to engraft and integrate in diseased murine kidneys, 26	
with resulting beneficial effects on renal function and arrest of disease progression19. 27	
Metanephric mesenchyme-like RPCs generated by pluripotent stem cells also showed a 28	
14		
considerable differentiation potential in vitro and in vivo in the embryonic kidney72. Recently, 1	
RPCs derived from human iPSCs were tested in a murine model of AKI. Interestingly, they not 2	
only restored renal function but also showed a robust engraftment into damaged tubuli 3	
(Imberti). 4	
Cell therapy with adult RPCs 5	
 Pioneer experiments in acute models of tubular or glomerular damage showed a 6	
potential therapeutic effect of the administration of adult rat/murine RPCs of different type and 7	
origin 49,51-53,77 (Table III). Similarly, administering adult CD24+/CD133+ RPCs from the 8	
Bowman’s capsule, cortical tubular compartment, and inner medulla to immunodeficient mice 9	
with rhabdomyolysis-induced AKI was shown to have therapeutic benefits35,41,54,78 (Table IV). 10	
In these experiments, a single dose of CD133+ cells (ranging from 5x105 to 1x106 cells) was 11	
administered, after induction of renal damage. This cell therapy improved renal function, as 12	
shown by the rapid decrease of creatinine and blood urea, together with amelioration of tissue 13	
histology35,41,54,78. These results correlated closely with those commonly obtained using MSCs, 14	
and comparison of MSCs with medulla-derived CD133+ cells demonstrated an equivalent 15	
therapeutic effect78. However, a bio-distribution study showed that CD133+ cells preferentially 16	
localized to the kidney region, with less cell dispersion in other parenchymal organs, with 17	
respect to MSCs, when analysed by optical imaging 48 hours after injection78. Similarly, 18	
administration of CD133+CD24+ cells isolated from the Bowman’s capsule promoted renal 19	
amelioration in a model of FSGS, characterized by podocyte injury, reducing proteinuria and 20	
improving chronic glomerular damage40. This effect was restricted to undifferentiated 21	
CD133+CD24+PDX- cells, whereas no effect was observed using partly differentiated 22	
CD133+CD24+PDX+ renal cells, or CD133 negative cells40. Moreover, CD133+CD24+ cells 23	
isolated from urine similarly differentiated into podocytes and reduced proteinuria in the 24	
adriamycin model58. 25	
 Using the same glycerol-induced AKI model used for CD133+ RPCs, the therapeutic 26	
effect of NCAM+ RPC overexpressed markers of fetal RPCs was compared with that of the 27	
total human kidney epithelial cell culture, uniformly positive for CD24/CD133. Both populations 28	
displayed a therapeutic effect, with no difference between NCAM+ and NCAM- cells57. 29	
15		
 This observation may suggest a possible effect for cell therapy using renal epithelial 1	
cells, as reported below. By analogy mature tubular epithelial renal-like cells, obtained from 2	
differentiation of spermatogonial derived embryonic-like stem cells, protected against acute and 3	
subsequent chronic damage in vivo in a model of kidney ischaemia79. However, the he 4	
administration of human CD133 negative cells did not provide benefit in tubular or glomerular 5	
acute damage35,40,41. As the CD133 negative population was not fully characterized, it can not 6	
be determined whether the lack of a therapeutic effect may be related to the activity of 7	
fibroblasts or rather of renal epithelial cells.  8	
Mechanisms of action of RPCs 9	
 An intriguing point of discussion in renal regenerative medicine is the mechanism of 10	
effect of the administered cells. While the effect ascribed to MSCs is mainly related to 11	
paracrine delivery of soluble mediators and bioactive vesicles containing genetic material 12	
(mRNA and microRNA),80 mechanisms of both paracrine stimulation and tissue integration 13	
have been described for human RPCs. Detection of the injected adult RPCs in the kidneys of 14	
AKI mice was reported in both proximal and distal tubules35,41,54,. Analysis of cell integration 15	
after 11 days showed that around 7% of the total number of tubular cells co-expressed the 16	
labelling dye and tubule markers35. Similarly, in a model of podocyte damage, 17	
CD133+CD24+PDX- cells generated new podocytes, representing of all podocytes after 7 days 18	
11.08 ± 3.3%, and maintaining their engraftment after 45 days40. Interestingly, the ability to 19	
differentiate into podocytes was restricted to Bowmann’s capsule isolated RPCS, that also 20	
differentiated into tubular cells, whereas tubular derived RPCS cells did not41. However, RPCs 21	
isolated from inner medulla showed a limited persistence within the murine tissue at 1 month 22	
after the injection78. High tissue integration has been also reported for foetal RPCs directly 23	
injected into the renal parenchyma in a 5/6 nephrectomized kidney19. Tissue analysis showed 24	
three distinct patterns of engraftment: initially, RPCs were located within existing mouse 25	
tubules or within the interstitium, and after 3 months they tended to organise into large mature-26	
appearing epithelial tubules with a patent lumen, resembling segment nephrogenesis19. 27	
In addition, RPCs were described to release a large variety of growth factors and vesicles that 28	
may contribute to tissue repair. In particular IL-15, a kidney specific factor involved in renal 29	
16		
differentiation81, was selectively released by CD133+ cells78. RPC-derived extracellular 1	
vesicles may also be involved in the process of repair, as they promoted in vitro survival and 2	
proliferation in target epithelial cells82.  3	
 The data from the literature and also from our laboratory indicate a variable number of 4	
RPC engraftment within the tubules. Weather the cell engraftment in the kidney entirely 5	
accounts for repopulation of tubular cells is questionable as no more than 10-11% human cells 6	
are detected within regenerating tubules and the evidence for their differentiation in mature 7	
epithelial cells are weak. The relevance of RPC integration would require dedicated long term 8	
experiments. In fact, cell integration both in AKI and in CKD models was assessed only up to 2 9	
weeks. We suggest a combined mechanism of paracrine support and integration in the effects 10	
of RPCs observed in pre-clinical studies. It is conceivable that the engrafted RPCs may 11	
coordinate the endogenous repair.   12	
It could be hypothesized that a paracrine mechanism, as described for MSCs, could be 13	
sufficient for a therapeutic effect in AKI. This was also confirmed for kidney-derived MSCs as 14	
the therapeutic effects were recapitulated by administration of kidney-MSC-derived 15	
extracellular vesicles83,84. Indeed, in acute damage, activation of resident responsive 16	
regenerative cells could be sufficient to support repair. At variance, the integration mechanisms 17	
of RPCs find a specific need in CKD, as regenerating responsive cells could be exosted and 18	
the integration of new functional cells to regain function would be required.  19	
 Therefore, in acute settings, the use of MSCs appears clinically more applicable than 20	
that of RPCs, which show limited cell sources and expansion, undefined culture conditions, and 21	
poorly accessible or inadequate autologous tissue. In chronic settings, RPCs that are 22	
committed to the generation of nephron cells would represent the ideal cell type to obtain 23	
clinically-relevant beneficial effects. In addition, the use of patient-derived RPCs, from tissue or 24	
from urine, could have significant relevance in CKD as a possible autologous therapy that does 25	
not require immunosuppression. It would be of interest to test the effect of adult RPCs in a 26	
model of CKD characterized by nephron loss such as the 5/6 nephrectomy used for foetal 27	
RPCs19. In addition, data on the application of RPCs of adult and foetal sources should be 28	
obtained, and comparatively analysed.  29	
17		
 Differential results may also relay on different modalities of cell delivery. Is it well 1	
established that i.v. injected cells may be entrapped in the lungs and liver and thus release 2	
pacrine factors from this distal sites. In addition, i.v. or intra-arterially delivered cells need to 3	
overcome two basement membranes to reach the tubular compartment. This appears 4	
achievable in acute injury, when those barriers are partly damaged due to tissue injury. At 5	
variance, during chronic injury, an intra-parenchymal application may be necessary for 6	
localization of injected cells within the nephron. Indeed, intra-parenchymal delivery was chosen 7	
to administer RPCs or differentiated tubular cells in models of murine CKD (Table III and IV). 8	
This route of administration presents the advantage to require a low number of cells and to 9	
avoid cell dispersion in undesired organs. In contrast, it might be associated with adverse 10	
events such as local necrosis, thrombosis and limited distribution of the cells within the kidney. 11	
Cell therapy with adult renal-derived cells  12	
 Interestingly, a therapeutic effect of administering adult differentiated cell populations 13	
isolated from normal kidneys has been reported by a number of studies. Human renal cultures 14	
enriched in erythropoietin-positive cells were administered to the renal parenchyma in a model 15	
of chronic renal damage85. Results showed that these cells improved renal function and 16	
reduced renal fibrosis and inflammation, unlike erythropoietin-depleted cells. However, cells did 17	
not survive up to 12 weeks, suggesting a rapid paracrine effect. Other studies indicated the 18	
therapeutic effect of a tubular cell-enriched renal cell population86. Indeed, intra-parenchymal 19	
injection of isolated and cultured epithelial cells to mice with established chronic kidney injury 20	
improved renal function, extended survival and reduced the severity of kidney tissue pathology. 21	
This epithelial cell subpopulation was mainly composed of cells from the tubular and collecting 22	
duct and was depleted of glomerular, vascular and erythropoietin-producing cells. Similarly, a 23	
rat tubule-enriched epithelial cell population promoted regeneration in diabetic rats when 24	
injected intra-parenchymally, and stabilized disease progression up to 1-year post-treatment87. 25	
The mechanism ascribed to the therapeutic effect of the intra-parenchymal injected cells in 26	
CKD mice kidney was the activation of a regenerative response process. In particular, after 3 to 27	
6 weeks, a number of genes were upregulated including the pluripotency-associated SOX2 28	
gene and the RPC gene CD2488. These data could possibly  support the regenerative capacity 29	
of differentiated cells, as proposed by Kusaba et al26. 30	
18		
The strategy of intraparenchymal injection of adult renal cells is under investigation in a phase I 1	
trial in human patients suffering from CKD, using expanded autologous renal cells (Neo-Kidney 2	
Augment™ Cellular Therapy; ClinicalTrials.gov Identifier: NCT01846715). Human cells were 3	
isolated by biopsies from patients and expanded following a described protocol that allowed 4	
generation of an injectable large number of cells89. The obtained bioactive renal cells 5	
embedded into gelatine hydrogels were intra-parenchymally administered to patients (5 to 6	
date). The results of this trial have not yet been published. It will certainly be of interest to 7	
acquire knowledge on the mechanisms involved in the therapeutic effects of the administered 8	
cells, taking into account a possible, although limited, cell dedifferentiation into RPCs.  9	
 10	
Conclusions and perspectives 11	
 While foetal cells with nephron-forming activity have been characterized in terms of 12	
molecular profile, the nature of the cells involved in kidney homeostasis/regeneration is 13	
unclear67, and further studies are required to understand the mechanisms involved in their 14	
possible activation. Adult human RPCs isolated from different nephron compartments appear 15	
to display progenitor-like properties, and provided a therapeutic effect in models of acute and 16	
chronic renal damage35,40,41,54,76. In acute pre-clinical models, their therapeutic efficacy was 17	
comparable to MSCs76, which, in turn, may benefit from more readily-available sources and 18	
reduced immune compatibility issues (Figure 1).  19	
 Although adult RPCs successfully engrafted within the renal tissue in acute models, their 20	
effect in a model of CKD with nephron loss needs to be established. Indeed, as they are 21	
committed to the kidney cell progeny, they could obviate the potential development of 22	
inappropriate cell types, and they would represent an ideal cell type to obtain clinically-relevant 23	
beneficial effects in patients with renal failure. However, the source of these cells is limited and 24	
they possess a short life span, undergo senescence over time and have a restricted 25	
nephrogenic potential.  26	
 Foetal-like RPCs with nephrogenic potential seem to be the ideal cell type for cell-based 27	
therapy in CKD. The in vitro generation of renal progenitors by iPS differentiation is of particular 28	
interest to overcome ethical issue and to get autologous tissue. However, it not only requires 29	
19		
complex and long differentiation passages, but it also has the limitation that once differentiated, 1	
progenitors do not proliferate in culture. The direct reprogramming of renal cells into induced 2	
RPCs may overcome this issue and generate expandable progenitors with high transfection 3	
efficacy. However, at present, no long-term culture system has proven to be capable of 4	
maintaining potent expansion of human adult progenitors over an extended period. Finally, 5	
adult renal cells unexpectedly appeared to be of therapeutic potential, and could be considered 6	
as a possible simple alternative for kidney regeneration. Increasing information on the nature of 7	
this population, including the presence of RPCs, and on the mechanism of action, is required. 8	
 9	10	
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Key points: RPC characterization 2	
 3	
• Embryonic progenitors represent the prototype of the renal cell population, with 4	
nephrogenic potential towards all the different types of nephron epithelia.  5	
 6	
• In the adult kidney, the nephrogenic mesenchymal progenitor population is absent. 7	
 8	
• Adult RPCs appear as segment-restricted progenitors. Whether they are a fixed 9	
population or rather a transient functional state modulated by microenvironmental stimuli 10	
is still unclear. 11	
 12	
• Human CD133+ cells with phenotypic and functional progenitor-like properties are 13	
present in all nephron segments as scattered distinct cells with a dedifferentiated 14	
phenotype, and survive and proliferate after damage.  15	
 16	
• Adult RPC cultures have been obtained by different nephron compartments or by urine 17	
and show homogeneous characteristics in vitro although distinct integration potential in 18	
pre-clinical models, possibly due to segment commitment.   19	
 20	
• All the cell lines of human RPCs possess a limited life span and undergo senescence 21	
over time. 22	
 23	
 24	
 25	
Key points: Acquired knowledge and limitations of RPC therapy 26	
 27	
• Pro: Concerted efforts have been employed in developing the technology to generate 28	
metanephric mesenchyme progenitors by differentiation of pluripotent stem cells or by 29	
direct reprogramming of renal cells.  30	
 Con: Maldifferentiation, oncogenic potential and expansion limits may impair their 31	
 application. 32	
 33	
• Pro: Adult human RPCs show therapeutic potential in acute tubular and glomerular 34	
damage due to both paracrine mechanisms and differentiation.  35	
Con: No differences are observed in pre-clinical models with respect to MSCs, although 36	
these cells lack integration potential. MSCs may benefit from more readily-available 37	
sources and reduced immune compatibility issues.   38	
 39	
• Pro: Adult and foetal RPCs show long-term engraftment in glomeruli and tubules, in pre-40	
clinical models of CKD and possibly a low risk of maldifferentiation. The generation of 41	
29		
patient-derived RPCs could have significant relevance in chronic settings as a possible 1	
autologous therapy that does not require immunosuppression. 2	
Con: Knowledge of the differentiation, integration potential and persistence of the 3	
different cell types is still required. 4	
 5	
• Pro: Adult sources of renal cells were shown to be beneficial in CKD and are currently 6	
undergoing a phase 1 clinical trial using an intra-parenchymal injection of autologous 7	
cells. 8	
 Con: Cells derived from CKD patients may lose regenerative ability, and  additional 9	
 reprogramming technology could be required. Mechanisms involved should be 10	
 investigated more fully. 11	
 12	
• The administration modalities for cell therapy with RPCs needs to be defined. As tubular 13	
localization requires the passage trough glomerular or tubular basal membrane, a local 14	
administration appears more feasible.   15	
Pro. Reduced cell number required, reduce extra-renal localization 16	
Con. Possible local damage (necrosis or thrombosis), local rather than general diffusion 17	
of cells.  18	19	
30		
 1	
Table I. Identification of RPCs in renal rodent or human tissue using different markers or 2	
functional tools. Localization within nephron districts and evidences of in vivo function are 3	
indicated. 4	
 Identification 
tool 
Tissue location Tissue function In vitro 
culture 
Refs 
M
ur
in
e/
ra
t t
is
su
e 
Scattered cells 
in PEC-rtTA 
mice 
BC, PT, DT Proliferation after injury n.d. 27,28 
Sca-1 interstitium - multipotency 53 
BrdU retention 
(short chase) 
PT, TL-HL, 
 DT, CD 
Proliferation after 
injury epithelial diff. 29 
BrdU retention 
(long chase) papilla 
Proliferation/ 
migration after injury multipotency,  30 
Side population PT - multipotency 52 
Lgr5 TL-HL and DT - n.d. 15 
nFatC1+ PT 
apoptosis-
resistance 
proliferation and 
repair 
n.d. 27 31 
c-kit TL-HL and DT  multipotency  32 
hu
m
an
 
tis
su
e 
CD133+/CD24+ BC, PT, HL, DT 
apoptosis-
resistance 
proliferation 
multipotency 3, 36-41 
Abbreviations: BC: Bowmann’s capule, PT: proximal tubules, TL-HL: thick segment of the 5	
Henle’s loop, HL: Henle’s loop, DT: distal tubules, CD: connecting ducts. 6	
 7	
 8	
 9	
 10	
 11	
 12	
 13	
 14	
 15	
 16	
 17	
 18	
 19	
 20	
 21	
 22	
 23	
 24	
 25	
 26	
31		
 1	
 2	
 3	
Table II. Localization of CD133+ RPCs in different nephron districts, and marker co-4	
expression. 5	
Nephron 
district 
Tissue 
location Markers  
Co-expression of 
scattered cell 
markers 
Co-expression 
of segment 
markers 
Re
fs 
Bowmann’s 
capsule 
Tubular 
pole 
CD133+/CD24+/ 
PDX - 
Vimentin 
Collagen 7A 
Claudin-1 
no 
21 
39 
40 
 
Proximal 
Tubules 
Tubular 
plicae 
CD133+/CD24+/C
D106+ 
 
Vimentin 
CK7, CK19 
Collagen 7A 
Claudin-1, 3 and 7 
annexin 2, S100A6 
CXCR4 
Megalin 
Aquaporin-1 
 
3 
36 
37  
39
41 
Henle’s loop Segments and loop  
CD133+ 
Nestin+ - no 
36 
38 
Distal 
tubules 
In contact 
with the 
glomerular 
vascular 
pole 
CD133+/ 
CD24+ - 
Thiazide-
sensitive Na/Cl 
cotransporter 
41 
Abbreviations: PDX: podocalixin, CXCR4: C-X-C chemokine receptor type 4 , CK: cytokeratin. 6	7	
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Table III. Cell therapy using rodent renal-derived cells in pre-clinical models of AKI and CKD. 3	
 4	
 Cell type Model administration Benefit  Mechanism ref 
ad
ul
t R
PC
s 
S3-derived 
tubular RPCs 
IRI  
subcapsule 
Improvement 
of renal 
function 
Tubular 
integration/ 
Paracrine 
49, 
75 cisplatin 
Multipotent 
RPCs IRI intra-arterially 
Improvement 
of renal 
function 
Tubular integration  
No paracrine 51 
Tubule-derived 
side population 
cells 
adriamycin I.V. and intra-parenchymal  
Reduced 
albuminuria Paracrine 52 
kidney-derived 
MSCs IRI I.V. 
Improvement 
of renal 
function and of 
angiogenesis 
Paracrine 
EV release 
83, 
84 
Sca-1 
interstitial cells IRI 
Intra-
parenchymal 
Improvement 
of renal 
function 
Tubular 
integration 53 
A
du
lt 
re
na
l c
el
ls
 Human EPO+ 
cells 
IRI and 
gentamycin 
Intra-
parenchymal 
Improvement 
of renal 
function-
Reduction of 
fibrosis 
Paracrine 85 
Rat renal cells 5/6 neph.  
intra-
parenchymal 
Reduction of 
disease 
progression  
Tubule 
Integration/ 
Paracrine 
86 
Rat renal cells Diabetes intra-parenchymal 
Reduction of 
disease 
progression 
Tubule 
Integration/ 
Paracrine 
87 
ES
C
- 
di
ffe
re
nt
ia
te
d 
ce
lls
 
Tubular 
differentiated-
spermatogonia
l stem cells 
 IRI Intra-parenchymal 
Improvement 
of function-
reduced 
development 
of fibrosis 
Paracrine 79 
Abbreviations: MSCs: mesenchymal stromal cells, IRI: ischemia-reperfusion injury, 5/6 neph.: 5	
5/6 nephrectomy, EPO: erythropoietin, I.V.: intravenously.  6	
 7	
 8	
 9	10	
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Table IV. Cell therapy using human renal-derived cells in pre-clinical models of AKI and CKD. 1	
 Cell type Model adminis
tration 
Benefit  Mechanism ref 
Fo
et
al
 R
PC
s Foetal 
CD133+/CD24+  
RPCs 
AKI 
(glycerol) i.v. 
Improvement 
of renal 
function 
Tubular 
integration 21 
Fetal NCAM+ 
RPCs 
CKD 
(5/6 neph.) 
Intra-
parenchy
mal 
Prevention of 
disease 
progression 
Tubular 
integration 19 
A
du
lt 
R
PC
s 
Bowmann’s 
capsule 
CD133+/CD24+/P
DX- RPCs 
FSGS 
(adryam.) i.v. 
Improvement 
of function- 
reduced 
fibrosis 
Podocytic/ 
Tubular 
integration 
40 
 
 
 
35 AKI (glycerol) i.v. 
Improvement 
of function 
Tubular 
integration 
Cortical 
CD133+/CD24+/ 
CD106+ RPCs 
FSGS 
(adryam.) i.v. Improvement 
of function 
Tubular 
differentiation 
only 
41 AKI 
(glycerol) i.v. 
Cortical CD133+ 
RPCs 
AKI 
(glycerol) i.v. 
Improvement 
of function 
Tubular 
differentiation 54 
Medullary CD133+ 
RPCs 
AKI 
(glycerol) i.v. 
Improvement 
of function 
Tubular 
integration/ 
paracrine 
36,78 
Urine 
CD133+/CD24+ 
RPCs 
FSGS 
(adryam.) i.v. 
Improvement 
of function 
Podocytic/ 
Tubular 
integration 
58 
NCAM+ RPCs AKI (glycerol) i.v. 
Improvement 
of function - 19 
A
du
lt 
re
na
l c
el
ls
  
Renal CD24-
/CD133- cells  
 
FSGS 
(adryam.) i.v. 
No 
improvement 
of renal 
function 
- 
35 
40 
41 
 
 
 
40 
AKI 
(glycerol) i.v. 
Bowmann’s 
capsule 
CD133+/CD24+/ 
PDX+ cells  
FSGS 
(adryam.) i.v. 
NCAM- cells from 
total epithelial cell 
culture 
AKI 
(glycerol) i.v. 
Improvement 
of function 
- 
19 
iP
S-
de
riv
ed
 
R
PC
s iPS-derived RPCs 
 
AKI 
(Cisplatin) i.v. 
Improvement 
of function 
Tubular 
differentiation ref 
Abbreviations: PDX: podocalixin, FSGS: focal segmental glomeruloscerosis, induced by 2	
administration of adriamycin (adryam.).  5/6 nephrectomy: 5/6 neph. IRI: ischemia-reperfusion 3	
injury. 4	5	
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 1	
Legend for Figure  2	
 3	
Figure 1. Potential strategies of cell therapy for kidney regeneration. Abbreviations: GPSC, 4	
germline cell-derived pluripotent stem cells; iPS, induced pluripotent stem cells; ESC: 5	
embryonic stem cells; EPO: erythropoietin. 6	
 7	
 8	
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